Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
HIV infection.
|
|
Dosage/Direction for Use
Adult: PO Combined with other antiretrovirals: 1.25 g bid or 0.75 g tid.
|
|
Administration
Should be taken with food.
|
|
Contraindications
Hypersensitivity; lactation.
|
|
Special Precautions
Pregnancy. Hepatic and renal impairment; haemophilia A or B; diabetes. Monitor for signs of lipodystrophy.
|
|
Adverse Reactions
Hyperglycaemia, dyslipidaemia and redistribution of body fat (protease paunch, buffalo hump, facial atrophy and heart engorgement); hypertriglyceridaemia, hypercholesterolaemia. Diarrhoea, rash, nausea, flatulence, decreased lymphocytes, decreased neutrophils, decreased haemoglobin, increased creatine kinase, increased transaminases.
|
|
Drug Interactions
Reduced levels/effects with antacids, phenobarbital, carbamazepine, aminoglutethimide, phenytoin, rifampicin, nafcillin, nevirapine, omeprazole, nevirapine. Increased serum levels/effects with azole antifungal agents, cimetidine, efavirenz. Increased serum levels/effects of azithromycin, calcium channel blockers, clarithromycin, corticosteroids (e.g. fluticasone), mirtazapine, nateglinide, nefazodone, ciclosporin, sirolimus, tacrolimus, venlafaxine, eplerinone, fentanyl, atorvastatin, phosphodiesterase-5 (PDE-5) inhibitors, rifabutin, trazodone, TCAs. Reduced serum levels/effects of hormonal contraceptives, methadone, theophylline derivatives.
|
|
CIMS Class
|
|
ATC Classification
J05AE04 - nelfinavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections.
|
